NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$29.82
+1.05 (+3.65%)
Close of Nov 06, 2026 · end-of-day data
SDGR 8-K filings in 2025
Every material Form 8-K Schrödinger filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Schrödinger reported third-quarter 2025 total revenue of $54.3 million, up 54% from a year earlier, and a net loss of $32.8 million, narrower than the $38.1 million loss in the prior-year quarter. The company lowered its full-year 2025 software revenue growth guidance to 8% to 13% from 10% to 15%, and said it expects savings of approximately $70 million from expense-reduction measures and a shift away from independent clinical development.
Q3 total revenue was $54.3 million, up 54%; software revenue was $40.9 million, up 28%, and drug discovery revenue was $13.5 million versus $3.4 million a year earlier.
Full-year 2025 software revenue growth guidance was cut to 8% to 13% from 10% to 15%, while drug discovery revenue guidance was raised to $49 million to $52 million from $45 million to $50 million.
Q3 net loss was $32.8 million, versus $38.1 million in Q3 2024; non-GAAP net loss was $42.3 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $401.0 million at September 30, 2025.
Schrodinger entered a separation agreement dated September 5, 2025 with Geoffrey Porges, its former Executive Vice President and Chief Financial Officer, after his previously disclosed departure. The agreement sets out severance payments and benefits that are described as substantially comparable to those in his prior employment agreement and the company's severance plan, with a mutual release of claims. The filing does not name a replacement CFO.
Separation agreement with Dr. Porges dated September 5, 2025, with payments conditioned on a seven-day revocation period
Salary continuation for nine months, and company-paid COBRA premium coverage for 12 months
Schrödinger reported second-quarter 2025 total revenue of $54.8 million, up 16% from a year earlier, and a net loss of $43.2 million, narrower than the $54.0 million loss in the second quarter of 2024. The company kept its 2025 revenue growth guidance and lowered its operating expense outlook, though software gross margin fell to 68% from 80%.
Total revenue rose 16% to $54.8 million from $47.3 million; software revenue rose 15% to $40.5 million.
Net loss was $43.2 million versus $54.0 million a year earlier; software gross margin fell to 68% from 80%.
Software revenue growth guidance of 10% to 15% and drug discovery revenue guidance of $45 million to $50 million were reaffirmed; operating expense guidance was lowered and 2025 operating expenses are now expected to be lower than 2024.
Schrodinger appointed Richie Jain, previously its senior vice president of strategic finance, as executive vice president and chief financial officer effective May 16, 2025. The company said CFO Geoffrey Porges is leaving the role to pursue other opportunities, and he will stay on as an advisor through June 6, 2025 to support the transition.
Richie Jain appointed CFO and Treasurer effective May 16, 2025; base salary $535,000
Jain eligible for a 2025-only target bonus of up to 55% of annualized base salary, prorated
Company expects to grant Jain an option on up to 18,750 shares and 9,375 restricted stock units
Geoffrey Porges separates from CFO role; remains employed as advisor through June 6, 2025
Schrödinger reported first-quarter 2025 total revenue of $59.6 million, up 63% from $36.6 million a year earlier, led by software revenue of $48.8 million. The net loss widened to $59.8 million from $54.7 million, and the loss per share was $0.82 compared with $0.76. The company maintained its previously issued 2025 financial guidance.
Total revenue rose 63% to $59.6 million; software revenue rose 46% to $48.8 million, partly due to early renewals by large customers.
Net loss was $59.8 million versus $54.7 million a year earlier; loss per share was $0.82 versus $0.76.
Non-GAAP net loss was $46.7 million versus $62.4 million in the first quarter of 2024.
Full-year 2025 guidance was maintained, including software revenue growth of 10% to 15% and drug discovery revenue of $45 million to $50 million.
Schrodinger's board elected Bridget van Kralingen as a director effective March 7, 2025, filling a seat on the board. She brings a background in technology and financial services, having previously held senior roles at IBM and Deloitte Consulting and currently serving as a Senior Partner at Motive Partners.
Board elected Bridget van Kralingen as a class II director effective March 7, 2025, with a term expiring at the 2025 annual meeting
She will receive a nonqualified stock option for 17,050 shares at an exercise price of $21.02 and restricted stock units for 10,000 shares under the non-employee director compensation policy
She will sign the company's standard indemnification agreement, which may require the company to cover certain expenses and judgments tied to her board service
Schrödinger reported fourth-quarter and full-year 2024 results and gave 2025 guidance. Full-year total revenue fell 4.2% to $207.5 million, with software revenue up 13.3% and drug discovery revenue down 53%, and the company posted a $187.1 million net loss after 2023 net income of $40.7 million. For shareholders, the results mix growing software sales and a higher fourth-quarter revenue total with wider losses and a sharply lower drug discovery contribution.
Full-year software revenue rose 13.3% to $180.4 million, while drug discovery revenue fell 53% to $27.2 million.
Full-year net loss was $187.1 million, compared with net income of $40.7 million in 2023; 2023 included a $147.2 million gain on equity investments.
Fourth-quarter total revenue rose 19.1% to $88.3 million, but the fourth-quarter net loss widened to $40.2 million from $30.7 million.
For 2025, the company expects software revenue growth of 10% to 15% and drug discovery revenue of $45 million to $50 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Schrödinger filing is on SEC EDGAR ↗. 8-K briefs of other companies →